Specify a stock or a cryptocurrency in the search bar to get a summary
Briacell Therapeutics Corp
BCTXWBriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Analytics
WallStreet Target Price
27.16 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BCTXW
Dividend Analytics BCTXW
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BCTXW
Stock Valuation BCTXW
Financials BCTXW
Results | 2019 | Dynamics |